Sedana Medical AB (publ), Interim report Q1, 2019
Clear regulatory pathway to approval in EU and USAFirst quarter, January - March 2019 · Net sales during the first quarter amounted to KSEK 17,814 (15,487) corresponding to an increase of 15% compared with the same period in 2018. · Earnings before interest, taxes, depreciation and amortisation (EBITDA) amounted to KSEK -2,641 (-788) KSEK. This corresponds to an EBITDA margin of -14,8% (-5,1%). · Earnings before interest and taxes (EBIT) amounted to KSEK -3,660 (-1,730), which corresponds to an EBIT margin of -20,5% (-11,2%) · Cash flow from operations before changes